粪便SDC2基因甲基化检测在结直肠肿瘤早期检测中的应用价值

doi:10.3969/j.issn.2095-378X.2020.01.003

外科研究与新技术 ›› 2020, Vol. 9 ›› Issue (1): 10-13.doi: 10.3969/j.issn.2095-378X.2020.01.003

粪便SDC2基因甲基化检测在结直肠肿瘤早期检测中的应用价值

李创坤¹, 黄颖烽², 邹瞭南³, 李筱颖⁴, 罗杰⁵, 牛凤¹, 赵日升⁶, 王怀明¹, 王辉¹, 黄榕康¹

1.中山大学附属第六医院结直肠外科,广东广州 510655;
2.广州市第十二人民医院普外科,广东广州 510620;
3.广东省中医院珠海医院肛肠外科,广东珠海 519015;
4.江门市五邑中医院脾胃病科,广东江门 529000;
5.上海国际医学中心内科,上海 200120;
6.中山大学附属第一医院胃肠外科,广东广州 510080

收稿日期:2020-03-03 发布日期:2020-09-12
通讯作者: 黄榕康,电子信箱：huangrk3@mail.sysu.edu.cn
作者简介:李创坤（1994—）,男,硕士研究生在读,从事临床结直肠外科工作

Application value of fecal SDC2 gene methylation test in early colorectal tumor diagnosis

LI Chuangkun¹, HUANG Yingfeng², ZOU Liaonan³, LI Xiaoying⁴, LUO Jie⁵, NIU Feng¹, ZHAO Risheng⁶, WANG Huaiming¹, WANG Hui¹, HUANG Rongkang¹

1. Department of Colorectal Surgery, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou 510620, Guangdong, China;
2. Department of General Surgery, Guangzhou 12th People's Hospital, Guangzhou 510620, Guangdong, CHina;
3. Department of Anorectal Surgery, Guandong Province Hospital of Traditional Chinese Medicine Zhuhai Branch, Zhuhai 519015, Guangdong, China;
4. Department of Spleen and Gastroenterology, Jiangmen Hospital of Traditional Chinese Medicine, Jiangmen 529000, Guangdong, China;
5. Department of Internal Medicine, Shanghai International Medical Center, Shanghai 200120, China;
6. Department of Gastrointestinal Surgery, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, Guangdong, China

Received:2020-03-03 Published:2020-09-12

摘要/Abstract

摘要： 目的探讨粪便SDC2基因甲基化检测在结直肠肿瘤早期检测中的价值。方法收集2018年1月—2018年12月收治的134例入组人群的病历资料,观察和比较粪便SDC2基因甲基化和血清癌胚抗原（CEA）两种检测方法对结直肠肿瘤诊断的灵敏度和特异度。结果 134例入组人群中,正常86例,结直肠腺瘤22例,结直肠癌26例。SDC2基因甲基化检测（长安心）阳性45例,阴性89例,血清CEA检测阳性16例,阴性118例。26例结直肠癌中SDC2基因甲基化检测阳性23例（88.46%）,血清CEA检测阳性7例（26.92%）,SDC2基因甲基化检测灵敏度高于血清CEA检测（P<0.001）。22例腺瘤患者中,SDC2基因甲基化检测阳性高于血清CEA检测（31.82% vs.4.54%,P =0.042）。结论相比血液CEA检测,粪便SDC2基因甲基化检测诊断结直肠癌及癌前病变有较高灵敏度,有待于扩大样本量对结直肠肿瘤早期诊断中价值作深入探讨。

关键词: 结直肠癌, 甲基化, SDC2基因, 早期检测

Abstract: Objective To investigate the value of fecal SDC2 gene methylation test in early colorectal tumor diagnosis. Methods Medical records data of 134 enrolled patients were collected from six hospitals from January 2018 to December 2018. The sensitivity and specificity between fecal SDC2 gene methylation test and serum carcinoembryonic antigen (CEA) test for early colorectal tumor diagnosis were compared. Results Of the 134 enrolled cases, 86 cases were without colorectal tumors, 22 cases with colorectal adenoma, and 26 cases with colorectal cancer. Fecal SDC2 gene methylation was detected positive in 45 patients and negative in 89 patients. Serum CEA was detected positive in 16 patients and negative in 118 patients. In the 26 patients with colorectal cancer, the positive rate of SDC2 gene methylation (88.46%) was higher than that of serum CEA (27.59%), indicating that the sensitivity of SDC2 gene methylation test was higher than that of serum CEA test for patients with colorectal cancer (P<0.001). In the 22 patients with colorectal adenoma, the positive rate of SDC2 gene methylation was higher than that of serum CEA (22.73% vs. 4.54%, P=0.185). Conclusion Compared with serum CEA test, fecal SDC2 gene methylation test has a higher sensitivity in the diagnosis of colorectal tumor and precancerous lesions, and its role in the early diagnosis of colorectal tumor requires to be investigated in a larger sample size.

Key words: Colorectal tumor, Methylation, SDC2 gene, Early diagnosis

中图分类号:

R656

李创坤, 黄颖烽, 邹瞭南, 李筱颖, 罗杰, 牛凤, 赵日升, 王怀明, 王辉, 黄榕康. 粪便SDC2基因甲基化检测在结直肠肿瘤早期检测中的应用价值[J]. 外科研究与新技术, 2020, 9(1): 10-13.

LI Chuangkun, HUANG Yingfeng, ZOU Liaonan, LI Xiaoying, LUO Jie, NIU Feng, ZHAO Risheng, WANG Huaiming, WANG Hui, HUANG Rongkang. Application value of fecal SDC2 gene methylation test in early colorectal tumor diagnosis[J]. Surgical Research and New Technique, 2020, 9(1): 10-13.

参考文献

[1] 夏晨静, 陈志荣. 粪便DNA甲基化检测对结直肠癌诊断及预后评估临床价值研究进展[J]. 临床军医杂志, 2019, 47(6):657-659.
[2] Bray F, Ferlay J, Soerjomataram I, et al.Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,2018,68(6):394-424.
[3] Chen W, Zheng R, Zeng H, et al.The incidence and mortality of major cancers in China, 2012[J]. Chin J Cancer,2016,35(1):73.
[4] 王裴,张明鑫,张超,等.粪便DNA甲基化检测在结直肠癌早期诊断中的研究进展[J].现代肿瘤医学,2015,23(6):874-880.
[5] 刘艳枚,杨梦,林金端,等.SDC2基因甲基化检测在结直肠癌早期诊断中的应用[J].深圳中西医结合杂志,2019,29(14):11-13.
[6] Kadiyska T, Nossikoff A.Stool DNA methylation assays in colorectal cancer screening[J]. World J Gastroenterol,2015,21(35):10057-10061.
[7] Ahlquist D A, Zou H, Domanico M, et al.Next-generation stool DNA test accurately detects colorectal cancer and large adenomas[J]. Gastroenterology,2012,142(2):248-256.
[8] Brenner H, Hoffmeister M, Arndt V, et al.Protection from right- and left-sided colorectal neoplasms after colonoscopy:population-based study[J]. J Natl Cancer Inst,2010,102(2):89-95.
[9] Provenzale D,Jasperson K,Ahnen D J,et al.Colorectal Cancer Screening,Version 1.2015[J]. J Natl Compr Canc Netw,2015,13(8):959-968.
[10] 文小霞,何磊.血清肿瘤标志物联合检测对结直肠癌的诊断意义[J].世界临床医学,2017,11(19):187.
[11] 矣金华,刘江,王昆华.结直肠癌CpG岛甲基化表型的研究进展[J].世界华人消化杂志,2016,24(4):558-565.
[12] 王强,郑海涛,丁德祥.结直肠癌的流行病学和筛查进展[J].中国现代医生,2008,46(18):103-104.
[13] Bosch L J, Carvalho B, Fijneman R J, et al.Molecular tests for colorectal cancer screening[J]. Clin Colorectal Cancer,2011,10(1):8-23.
[14] 张丽丽,吴建新.DNA甲基化——肿瘤产生的一种表观遗传学机制[J].遗传,2006,28(7):880-885.
[15] 赵慧霞,李秋文,董伟伟,等.粪便SEPT9基因甲基化检测在结直肠癌早期诊断中的应用研究[J].中华临床医师杂志(电子版),2012,6(10):2599-2602.
[16] Chen J,Sun H, Tang W, et al.DNA methylation biomarkers in stool for early screening of colorectal cancer[J]. J Cancer,2019,10(21):5264-5271.
[17] Castells A.Colorectal cancer screening[J].Gastroenterol Hepatol,2013,36(Suppl 2):66-72.
[18] Dickinson B T, Kisiel J, Ahlquist D A, et al.Molecular markers for colorectal cancer screening[J]. Gut,2015,64(9):1485-1494.
[19] Zou H, Allawi H, Cao X, et al.Quantification of methylated markers with a multiplex methylation-specific technology[J].Clin Chem,2012,58(2):375-383.
[20] Imperiale T F, Ransohoff D F, Itzkowitz S H, et al.Multitarget stool DNA testing for colorectal-cancer screening[J]. N Engl J Med,2014,370(14):1287-1297.
[21] 潘世扬. DNA甲基化标志物在分子诊断与治疗中的价值[J].分子诊断与治疗杂志,2009,1(3):145-147.

粪便SDC2基因甲基化检测在结直肠肿瘤早期检测中的应用价值

Application value of fecal SDC2 gene methylation test in early colorectal tumor diagnosis

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 14

编辑推荐

Metrics

本文评价

[1]	王晓娜, 林旭林, 林耿彬, 黄俊萍. 不同麻醉镇痛方式对腹腔镜结直肠癌根治术患者术后转归的影响[J]. 外科研究与新技术, 2021, 10(1): 57-60.
[2]	王晖, 王芳涛, 范跃祖. 抗淋巴管生成治疗结直肠癌研究进展[J]. 外科研究与新技术, 2021, 10(1): 64-67.
[3]	杨秀春, 王盼. 腹腔镜结直肠癌根治术治疗结直肠癌的近期疗效观察[J]. 外科研究与新技术, 2020, 9(1): 14-16.
[4]	贺雪, 殷佩浩. 结直肠癌患者血清miR-21检测的临床价值[J]. 外科研究与新技术, 2019, 8(1): 1-3.
[5]	孙璐, 王胜. 腹腔镜手术对结直肠癌患者免疫功能及手术并发症的影响[J]. 外科研究与新技术, 2018, 7(4): 229-231.
[6]	陆峰, 刘成宸, 陈威鹏. 结直肠癌手术并发症相关因素分析[J]. 外科研究与新技术, 2018, 7(4): 235-237.
[7]	包增涛, 唐强, 史文超, 周晓敏, 陈慧玉. 加速康复外科治疗改善结直肠癌患者营养及免疫功能[J]. 外科研究与新技术, 2018, 7(4): 238-240.
[8]	王茂生. 快速康复理念在全腹腔镜下结直肠癌微创手术中的应用[J]. 外科研究与新技术, 2017, 6(1): 15-17.
[9]	徐莹杨大明彭海霞周锋利李吉蒯榕. X线辅助下经结肠镜放置金属支架治疗结直肠癌梗阻的临床价值[J]. 外科研究与新技术, 2016, 5(2): 82-84,107.
[10]	徐梦娇童晓文. 游离DNA异常甲基化在卵巢癌中的研究进展[J]. 外科研究与新技术, 2016, 5(2): 132-135,138.
[11]	唐翀姜湉高雪松施文秦炜颜孙永强. 结直肠癌中ADAM-9的表达与预后的关系[J]. 外科研究与新技术, 2015, 4(4): 223-225.
[12]	王云峰（综述），尹路. 结直肠癌肝转移的早期诊断及外科微创治疗策略[J]. 外科研究与新技术, 2015, 4(1): 1-3.
[13]	张远威(综述)，黄雄(审校). 腹腔镜结直肠癌手术的治疗现状与展望[J]. 外科研究与新技术, 2013, 2(3): 177-179.
[14]	吴周睿, 胡笑, 徐委, 孙晓晴, 管晓菲, 程黎明. DNMT3B对人脐带间质干细胞成骨分化能力的影响[J]. 外科研究与新技术, 2012, 1(2): 103-107.